Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A
Latest Information Update: 26 Sep 2024
At a glance
- Drugs Damoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms HEM-POWR
- Sponsors Bayer
Most Recent Events
- 14 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Dec 2022 Results of post hoc analysis of this trial to explore the safety and effectiveness of extended dosing with damoctocog alfa pegol presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 09 Nov 2022 Results of post-hoc subgroup analysis (n=31; data cut-off 31 August 2021) assessing effectiveness and safety of damoctocog alfa pegol utilisation during routine clinical practice, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.